Hydroxyl Radical Protein Footprinting: A Mass Spectrometry-Based Structural Method for Studying the Higher Order Structure of Proteins

Hydroxyl Radical Protein Footprinting: A Mass Spectrometry-Based Structural Method for Studying the Higher Order Structure of Proteins

Hydroxyl radical protein footprinting (HRPF) coupled to mass spectrometry has been efficiently used to analyze a plethora of protein-related questions. The tactic, which makes use of hydroxyl radicals to oxidatively modify solvent-accessible amino acids, can inform on protein interplay websites and areas of conformational change.
Hydroxyl radical-based footprinting was initially developed to review nucleic acids, however coupling the tactic with mass spectrometry has enabled the research of proteins. The tactic has undergone a number of developments since its inception which have elevated its utility for extra diversified purposes corresponding to protein folding and the research of biotherapeutics.
As well as, current improvements have led to the research of more and more complicated techniques together with cell lysates and intact cells. Technological advances have additionally elevated throughput and allowed for higher management of experimental situations. On this assessment, we offer a short historical past of the sector of HRPF and element current improvements and purposes within the area.

Missense mutations involvement in COX-2 construction, and protein-substrate binding affinity: in-silico research

Cyclooxygenase-2 (COX-2) is an inducible inflammatory enzyme, which produces prostanoids from arachidonic acid. COX-2 overexpression and over-activity may cause irritation, tumorigenesis, and angiogenesis. Prostanoids are the primary motive for the irritation, and enhance of mitogenesis by COX-2.
So, any change corresponding to mutations that may result in COX-2 over-activity may ignite the tumor conditions with enhance of prostanoids manufacturing is considered one of its methods. The goal of this research was to test the impact of 166 missense mutations of COX-2 on protein options that may have an effect on the COX-2 exercise corresponding to protein stability, fluctuation, 2D construction, and its binding affinity with the substrate by in silico strategies, community modeling, and docking calculations, by which 44 of them proven to be deleterious.
Amongst them, the S124I and S474F mutations can enhance the soundness of the protein. 11.36% of deleterious nsSNPs have been a part of the substrate-binding area amongst which the M508T, H337R, and V511G have the potential to have an effect on the protein by 2D construction alteration.
V511G can enhance binding affinity and H337R confirmed a small lower within the deformation total vitality that may symbolize a lower within the stability of COX-2. Additionally, L517S confirmed a major lower within the binding energy of COX-2/substrate however primarily based on the anisotropic community modeling this mutation has a twin impact on COX-2 stability. These nsSNPs/mutations have the potential inflicting a rise or lower of tumorigenesis as a result of rising of COX-2 stability and its binding affinity can result in altering its exercise.

Cryo-EM construction willpower of small proteins by nanobody-binding scaffolds (Legobodies)

We describe a common methodology that permits construction willpower of small proteins by single-particle cryo-electron microscopy (cryo-EM). The tactic relies on the supply of a target-binding nanobody, which is then rigidly connected to 2 scaffolds: 1) a Fab fragment of an antibody directed in opposition to the nanobody and a pair of) a nanobody-binding protein A fraction fused to maltose binding protein and Fab-binding domains.
The general ensemble of ∼120 kDa, referred to as Legobody, doesn’t perturb the nanobody-target interplay, is well recognizable in EM pictures because of its distinctive form, and facilitates particle alignment in cryo-EM picture processing.
The utility of the tactic is demonstrated for the KDEL receptor, a 23-kDa membrane protein, leading to a map at 3.2-Å total decision with density enough for de novo mannequin constructing, and for the 22-kDa receptor-binding area (RBD) of SARS-CoV-2 spike protein, leading to a map at 3.6-Å decision that permits evaluation of the binding interface to the nanobody. The Legobody strategy thus overcomes the present dimension limitations of cryo-EM evaluation.

Human Surfactant Protein SP-A1 and SP-A2 Variants Differentially Have an effect on the Alveolar Microenvironment, Surfactant Construction, Regulation and Perform of the Alveolar Macrophage, and Animal and Human Survival Underneath Numerous Circumstances

The human innate host protection molecules, SP-A1 and SP-A2 variants, differentially have an effect on survival after an infection in mice and in lung transplant sufferers. SP-A interacts with the sentinel innate immune cell within the alveolus, the alveolar macrophage (AM), and modulates its perform and regulation.
SP-A additionally performs a task in pulmonary surfactant-related points, together with surfactant construction and reorganization. For many (if not all) pulmonary illnesses there’s a dysregulation of host protection and inflammatory processes and/or surfactant dysfunction or deficiency. As a result of SP-A performs a task in each of those common processes the place one or each might turn out to be aberrant in pulmonary illness, SP-A stands to be an essential molecule in well being and illness.
In people (in contrast to in rodents) SP-A is encoded by two genes (SFTPA1 and SFTPA2) and every has been recognized with in depth genetic and epigenetic complexity. On this assessment, we deal with practical, structural, and regulatory variations between the 2 SP-A gene-specific merchandise, SP-A1 and SP-A2, and amongst their corresponding variants.
We focus on the differential impression of those variants on the surfactant construction, the alveolar microenvironment, the regulation of epithelial kind II miRNome, the regulation and performance of the AM, the general survival of the organism after an infection, and others. Though there have been numerous critiques on SP-A, that is the primary assessment that gives such a complete account of the variations between human SP-A1 and SP-A2.
Hydroxyl Radical Protein Footprinting: A Mass Spectrometry-Based Structural Method for Studying the Higher Order Structure of Proteins

Advanced construction of the acyltransferase VinK and the service protein VinL with a pantetheine cross-linking probe

Acyltransferases are answerable for the choice and loading of acyl items onto service proteins in polyketide and fatty-acid biosynthesis. Regardless of the significance of protein-protein interactions between the acyltransferase and the service protein, structural info on acyltransferase-carrier protein interactions is proscribed due to the transient interactions between them.
Within the biosynthesis of the polyketide vicenistatin, the acyltransferase VinK acknowledges the service protein VinL for the switch of a dipeptidyl unit. The crystal construction of a VinK-VinL covalent complicated fashioned with a 1,2-bismaleimidoethane cross-linking reagent has been decided beforehand.
Right here, the crystal construction of a VinK-VinL covalent complicated fashioned with a pantetheine cross-linking probe is reported at 1.95 Å decision. Within the construction of the VinK-VinL-probe complicated, the pantetheine probe that’s connected to VinL is covalently linked to the aspect chain of the mutated Cys106 of VinK.

SARS-CoV Spike (Middle)

GWB-7B5EA5 1 mg Ask for price

SARS-CoV Spike Protein

abx060655-1mg 1 mg
EUR 2030.4

SARS-CoV Spike Protein

abx060655-100g 100 µg Ask for price

SARS-CoV Spike Protein

abx060655-10g 10 µg
EUR 1962.5

SARS-CoV Spike Protein

abx060655-50g 50 µg Ask for price

SARS-CoV Spike Protein

abx060656-100g 100 µg Ask for price

SARS-CoV Spike Protein

abx060656-10g 10 µg
EUR 1962.5

SARS-CoV Spike Protein

abx060656-50g 50 µg Ask for price

SARS-CoV Spike Protein

abx060657-100g 100 µg Ask for price

SARS-CoV Spike Protein

abx060657-10g 10 µg
EUR 1962.5

SARS-CoV Spike Protein

abx060657-50g 50 µg Ask for price

SARS-CoV Spike Antibody

21807 100ul
EUR 1039

SARS-CoV Spike Antibody

21808 100ul
EUR 1039

SARS-CoV Spike Antibody

21809 100ul
EUR 1039

SARS-CoV Spike Antibody

21810 100ul
EUR 1039

SARS-CoV Spike Antibody

21811 100ul
EUR 1039

SARS-CoV Spike Antibody

21812 100ul
EUR 1039

SARS-CoV Spike Antibody

3225-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3225-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3219-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3219-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3221-002mg 0.02 mg
EUR 206.18
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3221-01mg 0.1 mg
EUR 523.7
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3223-002mg 0.02 mg
EUR 206.18
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

3223-01mg 0.1 mg
EUR 523.7
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.

SARS-CoV Spike Antibody

MBS9457577-005mL 0.05mL
EUR 530

SARS-CoV Spike Antibody

MBS9457577-01mL 0.1mL
EUR 825

SARS-CoV Spike Antibody

MBS9457577-5x01mL 5x0.1mL
EUR 3560

SARS-CoV Spike Antibody

MBS9457578-005mL 0.05mL
EUR 530

SARS-CoV Spike Antibody

MBS9457578-01mL 0.1mL
EUR 825

SARS-CoV Spike Antibody

MBS9457578-5x01mL 5x0.1mL
EUR 3560

SARS-CoV Spike Antibody

MBS9457579-005mL 0.05mL
EUR 530

SARS-CoV Spike Antibody

MBS9457579-01mL 0.1mL
EUR 825

SARS-CoV Spike Antibody

MBS9457579-5x01mL 5x0.1mL
EUR 3560

SARS-CoV Spike Antibody

MBS9457580-005mL 0.05mL
EUR 530

SARS-CoV Spike Antibody

MBS9457580-01mL 0.1mL
EUR 825

SARS-CoV Spike Antibody

MBS9457580-5x01mL 5x0.1mL
EUR 3560

SARS-CoV Spike Antibody

MBS9457581-005mL 0.05mL
EUR 530

SARS-CoV Spike Antibody

MBS9457581-01mL 0.1mL
EUR 825

SARS-CoV Spike Antibody

MBS9457581-5x01mL 5x0.1mL
EUR 3560

SARS-CoV Spike Antibody

MBS9457582-005mL 0.05mL
EUR 530

SARS-CoV Spike Antibody

MBS9457582-01mL 0.1mL
EUR 825

SARS-CoV Spike Antibody

MBS9457582-5x01mL 5x0.1mL
EUR 3560

SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] 100 ul

BSV-COV-AB-02 100 ul
EUR 602
Description: SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal)

SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody

abx137719-100tests 100 tests
EUR 1237.5

SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody

abx137720-100tests 100 tests
EUR 1237.5

SARS CoV-2 IgM Spike S1 (CoV-2 IgM S1) Antibody

abx137721-100tests 100 tests
EUR 225

SARS-CoV-2 (COVID-19) Spike Antibody

3525-002mg 0.02 mg
EUR 206.18
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike Antibody

3525-01mg 0.1 mg
EUR 523.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) spike antibody

BSV-COV-AB-05 25 ul
EUR 286
Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal)

SARS-CoV-2 (COVID-19) spike antibody

BSV-COV-AB-06 100 ul
EUR 557
Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal)

SARS-CoV-2 (COVID-19) Spike 681P Antibody

9091-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike 681P Antibody

9091-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS CoV 2 Spike Protein (RBD), His tag, E.coli

E2S209916P 100ul
EUR 595
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

SARS-CoV Spike (N-term)

GWB-51A5A4 1 mg Ask for price

SARS-CoV Spike (C-term)

GWB-FCD9A4 1 mg Ask for price

SARS-CoV-2 Spike Peptide

9083P 0.05 mg
EUR 235.5
Description: (NT) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide

9087P 0.05 mg
EUR 235.5
Description: (CT) SARS-CoV-2 Spike RBD peptide

SARS-CoV-2 Spike Peptide

9091P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Peptide

9095P 0.05 mg
EUR 235.5
Description: (IN) SARS-CoV-2 Spike peptide

SARS-CoV-2 Spike Protein

abx655879-100g 100 µg
EUR 337.5

SARS-CoV-2 Spike Protein

abx655880-100g 100 µg
EUR 337.5

SARS-CoV-2 Spike Protein

abx655881-100g 100 µg
EUR 337.5

SARS-CoV-2 Spike Peptide

abx620083-100g 100 µg
EUR 250

SARS-CoV-2 Spike Peptide

abx620083-1mg 1 mg
EUR 1362.5

SARS-CoV-2 Spike Peptide

abx620083-200g 200 µg
EUR 350

SARS-CoV-2 Spike Peptide

abx620084-100g 100 µg
EUR 250

SARS-CoV-2 Spike Peptide

abx620084-1mg 1 mg
EUR 1362.5

SARS-CoV-2 Spike Peptide

abx620084-200g 200 µg
EUR 350

SARS-CoV-2 Spike Peptide

abx620085-100g 100 µg
EUR 250

SARS-CoV-2 Spike Peptide

abx620085-1mg 1 mg
EUR 1362.5

SARS-CoV-2 Spike Peptide

abx620085-200g 200 µg
EUR 350

SARS-CoV-2 Spike Peptide

abx620086-100g 100 µg
EUR 250

SARS-CoV-2 Spike Peptide

abx620086-1mg 1 mg
EUR 1362.5

SARS-CoV-2 Spike Peptide

abx620086-200g 200 µg
EUR 350

SARS-CoV-2 Spike Peptide

abx620087-100g 100 µg
EUR 250

SARS-CoV-2 Spike Peptide

abx620087-1mg 1 mg
EUR 1362.5

SARS-CoV-2 Spike Peptide

abx620087-200g 200 µg
EUR 350

SARS-CoV-2 Spike Peptide

abx620088-100g 100 µg
EUR 250

SARS-CoV-2 Spike Peptide

abx620088-1mg 1 mg
EUR 1362.5

SARS-CoV-2 Spike Peptide

abx620088-200g 200 µg
EUR 350

SARS-CoV-2 Spike Peptide

abx620089-100g 100 µg
EUR 250

SARS-CoV-2 Spike Peptide

abx620089-1mg 1 mg
EUR 1362.5

SARS-CoV-2 Spike Peptide

abx620089-200g 200 µg
EUR 350

SARS-CoV-2 Spike Peptide

MBS154644-005mg 0.05mg
EUR 205

SARS-CoV-2 Spike Peptide

MBS154644-5x005mg 5x0.05mg
EUR 900

SARS-CoV-2 Spike Peptide

MBS154645-005mg 0.05mg
EUR 205

SARS-CoV-2 Spike Peptide

MBS154645-5x005mg 5x0.05mg
EUR 900

SARS-CoV-2 Spike Peptide

MBS154646-005mg 0.05mg
EUR 205

SARS-CoV-2 Spike Peptide

MBS154646-5x005mg 5x0.05mg
EUR 900

SARS-CoV-2 Spike Peptide

MBS154655-005mg 0.05mg
EUR 205

SARS-CoV-2 Spike Peptide

MBS154655-5x005mg 5x0.05mg
EUR 900

SARS-CoV Spike Rabbit pAb

MBS9144354-002mL 0.02mL
EUR 200

SARS-CoV Spike Rabbit pAb

MBS9144354-005mL 0.05mL
EUR 255

SARS-CoV Spike Rabbit pAb

MBS9144354-01mL 0.1mL
EUR 345

SARS-CoV Spike Rabbit pAb

MBS9144354-02mL 0.2mL
EUR 545

SARS-CoV Spike Rabbit pAb

MBS9144354-5x02mL 5x0.2mL
EUR 2265

SARS-CoV Spike Rabbit pAb

A20605 20μL
EUR 88.56

SARS-CoV-2 Spike Antibody

10-2868 1 mg
EUR 1000
Description: SARS-CoV-2 Spike Antibody, Recombinant Human

SARS-CoV-2 Spike Antibody

10-2869 1 mg
EUR 1000
Description: SARS-CoV-2 Spike Antibody, Recombinant Human

SARS-CoV-2 Spike Antibody

10-2870 1 mg
EUR 1000
Description: SARS-CoV-2 Spike Antibody, Recombinant Human

SARS-CoV-2 Spike Antibody

10-2871 1 mg
EUR 1000
Description: SARS-CoV-2 Spike Antibody, Recombinant Human

SARS-CoV-2 Spike Antibody

10-2906 1 mg
EUR 225
Description: Anti-SARS-CoV-2 Spike Protein Monoclonal antibody

SARS-CoV-2 Spike Antibody

10-2907 1 mg
EUR 225
Description: Anti-SARS-CoV-2 Spike Protein Monoclonal antibody

SARS-CoV-2 Spike Antibody

abx229971-100g 100 µg
EUR 325

SARS-CoV-2 Spike, antibody

MBS664123-05mg 0.5mg
EUR 420

SARS-CoV-2 Spike, antibody

MBS664123-10mg 10mg
EUR 3605

SARS-CoV-2 Spike, antibody

MBS664123-15mg 15mg
EUR 5095

SARS-CoV-2 Spike, antibody

MBS664123-1mg 1mg
EUR 540

SARS-CoV-2 Spike, antibody

MBS664123-5mg 5mg
EUR 1960

SARS-CoV-2 Spike Antibody

MBS5316661-1mg 1mg
EUR 335

SARS-CoV-2 Spike Antibody

MBS5316661-5x1mg 5x1mg
EUR 1350

SARS-CoV-2 Spike Antibody

MBS5316705-1mg 1mg
EUR 335

SARS-CoV-2 Spike Antibody

MBS5316705-5x1mg 5x1mg
EUR 1350

SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb

MBS8110617-002mL 0.02mL
EUR 210

SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb

MBS8110617-01mL 0.1mL
EUR 480

SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb

MBS8110617-5x01mL 5x0.1mL
EUR 2010

SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb

MBS8119476-002mL 0.02mL
EUR 210

SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb

MBS8119476-01mL 0.1mL
EUR 480

SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb

MBS8119476-5x01mL 5x0.1mL
EUR 2010

SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb

MBS8119477-002mL 0.02mL
EUR 210

SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb

MBS8119477-01mL 0.1mL
EUR 480

SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb

MBS8119477-5x01mL 5x0.1mL
EUR 2010

SARS-CoV/SARS-CoV-2 Spike Antibody,Chimeric MAb

MBS8119480-002mL 0.02mL
EUR 210

SARS-CoV/SARS-CoV-2 Spike Antibody,Chimeric MAb

MBS8119480-01mL 0.1mL
EUR 480

SARS-CoV/SARS-CoV-2 Spike Antibody,Chimeric MAb

MBS8119480-5x01mL 5x0.1mL
EUR 2010

SARS-CoV/SARS-CoV-2 Spike Antibody, Chimeric MAb

MBS8574846-01mg 0.1mg
EUR 705

SARS-CoV/SARS-CoV-2 Spike Antibody, Chimeric MAb

MBS8574846-5x01mg 5x0.1mg
EUR 2910

SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb

MBS8574847-01mg 0.1mg
EUR 705

SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb

MBS8574847-5x01mg 5x0.1mg
EUR 2910
The interplay interface between VinK and VinL is actually the identical within the two VinK-VinL complicated buildings, though the place of the pantetheine linker barely differs. This structural statement means that interface interactions usually are not affected by the cross-linking technique used.

Leave a Reply

Your email address will not be published. Required fields are marked *